Cargando…
Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
Immunotherapy, represented by immune checkpoint inhibitors (ICI), is transforming the treatment of cancer. However, only a small percentage of patients show response to ICI, and there is an unmet need for biomarkers that will identify patients who are more likely to respond to immunotherapy. The fun...
Autores principales: | Wang, Shixiang, He, Zaoke, Wang, Xuan, Li, Huimin, Liu, Xue-Song |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879305/ https://www.ncbi.nlm.nih.gov/pubmed/31767055 http://dx.doi.org/10.7554/eLife.49020 |
Ejemplares similares
-
APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
por: Wang, Shixiang, et al.
Publicado: (2018) -
Can tumor mutational burden determine the most effective treatment for lung cancer patients?
por: Wang, Shixiang, et al.
Publicado: (2020) -
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors
por: Borchmann, Sven, et al.
Publicado: (2022) -
Rejection of immunogenic tumor clones is limited by clonal fraction
por: Gejman, Ron S, et al.
Publicado: (2018) -
Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer
por: Wang, Yejinpeng, et al.
Publicado: (2020)